WEBSITE BSE:544220 NSE: CTLLAB Inc. Year: 2010 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 00:00
No Notes Added Yet
Clinitech Laboratory Ltd is an Indian diagnostic services company founded in 1990. It operates a network of diagnostic centres in and around the Thane and Navi Mumbai region. The company offers a wide range of medical and health-related tests and services through its accredited laboratories. Its facilities are accredited by the National Accreditation Board for Testing and Calibration Laboratories under ISO standards, which underscores its commitment to quality and reliable test results. The company conducts more than three lakh medical tests an...Read More
Clinitech Laboratory Ltd is an Indian diagnostic services company founded in 1990. It operates a network of diagnostic centres in and around the Thane and Navi Mumbai region. The company offers a wide range of medical and health-related tests and services through its accredited laboratories. Its facilities are accredited by the National Accreditation Board for Testing and Calibration Laboratories under ISO standards, which underscores its commitment to quality and reliable test results. The company conducts more than three lakh medical tests annually across multiple test categories including biochemistry, immunology, hematology, molecular biology, serology, microbiology and histopathology. The diagnostic centres are equipped with modern technology and high-end laboratory equipment, and the business employs dozens of staff focused on delivering accurate and timely diagnostic data. The promoters of the company have over three decades of experience in the diagnostic healthcare sector, and the company pursued an initial public offering to raise capital to expand its diagnostic network and support general corporate purposes. Clinitech Laboratory serves patients, clinics and healthcare providers by offering comprehensive testing services designed to support preventive care, diagnosis and treatment planning. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹9 Cr.
Stock P/E 23.1
P/B 1
Current Price ₹40
Book Value ₹ 38.7
Face Value 10
52W High ₹57
Dividend Yield 0%
52W Low ₹ 28.6
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 5 | 6 | 6 | 6 | 8 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 5 | 6 | 6 | 6 | 8 | |
| Total Expenditure | 4 | 5 | 5 | 5 | 7 | |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | |
| Profit After Tax | 0 | 1 | 1 | 0 | 0 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 1 | 1 | 0 | 0 | |
| Adjusted Earnings Per Share | 2.7 | 3.4 | 4.1 | 2.2 | 1.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 33% | 10% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | -100% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -15% | NA% | NA% | NA% |
| ROE Average | 6% | 16% | 22% | 22% |
| ROCE Average | 9% | 18% | 24% | 24% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 1 | 2 | 2 | 4 | 9 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
| Total Current Liabilities | 1 | 1 | 2 | 2 | 2 |
| Total Liabilities | 3 | 4 | 6 | 5 | 11 |
| Fixed Assets | 1 | 2 | 1 | 2 | 2 |
| Other Non-Current Assets | 0 | 1 | 3 | 1 | 1 |
| Total Current Assets | 2 | 1 | 2 | 3 | 7 |
| Total Assets | 3 | 4 | 6 | 5 | 11 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 1 | 1 |
| Cash Flow from Operating Activities | 0 | 1 | 1 | -1 | -1 |
| Cash Flow from Investing Activities | 1 | -1 | -1 | 1 | -1 |
| Cash Flow from Financing Activities | -1 | 0 | 0 | 0 | 4 |
| Net Cash Inflow / Outflow | 0 | -0 | 1 | -0 | 2 |
| Closing Cash & Cash Equivalent | 0 | 0 | 1 | 1 | 3 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.68 | 3.42 | 4.09 | 2.21 | 1.73 |
| CEPS(Rs) | 4.32 | 5.96 | 7.06 | 4.82 | 3.7 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 9.27 | 12.32 | 15.87 | 21.12 | 38.69 |
| Core EBITDA Margin(%) | 18.2 | 16.73 | 21.48 | 15.63 | 10.1 |
| EBIT Margin(%) | 13.74 | 11.9 | 14.71 | 9.33 | 7.41 |
| Pre Tax Margin(%) | 11.98 | 11 | 13.61 | 7.89 | 6.74 |
| PAT Margin (%) | 8.84 | 8.03 | 9.66 | 5.8 | 4.79 |
| Cash Profit Margin (%) | 14.22 | 13.99 | 16.68 | 12.65 | 10.26 |
| ROA(%) | 15.21 | 16.47 | 12.97 | 6.56 | 4.94 |
| ROE(%) | 28.94 | 31.66 | 29 | 12.52 | 6.38 |
| ROCE(%) | 32.47 | 32.61 | 30.39 | 15.28 | 9.21 |
| Receivable days | 44.75 | 26.37 | 24.53 | 30.99 | 47.42 |
| Inventory Days | 7.14 | 7 | 8.54 | 12.12 | 18.01 |
| Payable days | 164.86 | 123.36 | 143.7 | 123.3 | 113.97 |
| PER(x) | 0 | 0 | 0 | 0 | 23.27 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 1.04 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.19 | 0.36 | 0.28 | 0.29 | 0.74 |
| EV/Core EBITDA(x) | 1.01 | 2 | 1.27 | 1.78 | 5.77 |
| Net Sales Growth(%) | 0 | 40.19 | -0.58 | 0.87 | 28.61 |
| EBIT Growth(%) | 0 | 21.46 | 22.83 | -35.97 | 2.02 |
| PAT Growth(%) | 0 | 27.39 | 19.61 | -39.46 | 6.33 |
| EPS Growth(%) | 0 | 27.37 | 19.61 | -45.94 | -21.73 |
| Debt/Equity(x) | 0.39 | 0.48 | 0.43 | 0.24 | 0 |
| Current Ratio(x) | 2.13 | 1.02 | 1.12 | 1.66 | 4.36 |
| Quick Ratio(x) | 2.01 | 0.9 | 1.04 | 1.49 | 4.05 |
| Interest Cover(x) | 7.82 | 13.15 | 13.37 | 6.46 | 11.07 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 61.58 | 61.58 | 62.42 | 64.2 |
| FII | 0.32 | 0.32 | 0.32 | 0.32 |
| DII | 0 | 0 | 0 | 0 |
| Public | 38.11 | 38.11 | 37.27 | 35.48 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 0.14 | 0.14 | 0.14 | 0.15 |
| FII | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 |
| Public | 0.09 | 0.09 | 0.09 | 0.08 |
| Others | 0 | 0 | 0 | 0 |
| Total | 0.23 | 0.23 | 0.23 | 0.23 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
